Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

A rationally designed self-immolative linker enhances the synergism between a polymer-rock inhibitor conjugate and neural progenitor cells in the treatment of spinal cord injury

  • Giraldo, Esther|||0000-0001-5488-3011
  • Nebot, V. J.
  • Dordevic, S.
  • Requejo-Aguilar, R.
  • Alastrue-Agudo, A.
  • Zagorodko, O.
  • Armiñán, A.
  • Martinez-Rojas, B.
  • Vicent, M.J.
  • Moreno Manzano, V.
[EN] Rho/ROCK signaling induced after spinal cord injury (SCI) contributes to secondary damage by promoting apoptosis, inflammation, and axon growth inhibition. The specific Rho-kinase inhibitor fasudil can contribute to functional regeneration after SCI, although inherent low stability has hampered its use. To improve the therapeutic potential of fasudil, we now describe a family of rationally-designed bioresponsive polymer-fasudil conjugates based on an understanding of the conditions after SCI, such as low pH, enhanced expression of specific proteases, and a reductive environment. Fasudil conjugated to poly-l-glutamate via a self-immolative redox-sensitive linker (PGA-SS-F) displays optimal release kinetics and, consequently, treatment with PGA-SS-F significantly induces neurite elongation and axon growth in dorsal root ganglia explants, spinal cord organotypic cultures, and neural precursor cells (NPCs). The intrathecal administration of PGA-SS-F after SCI in a rat model prevents early apoptosis and induces the expression of axonal growth- and neuroplasticity-associated markers to a higher extent than the free form of fasudil. Moreover, a combination treatment comprising the acute transplantation of NPCs pre-treated with PGA-SS-F leads to enhanced cell engraftment and reduced cyst formation after SCI. In chronic SCI, combinatory treatment increases the preservation of neuronal fibers. Overall, this synergistic combinatorial strategy may represent a potentially efficient clinical approach to SCI treatment., This research was funded by FEDER/Ministerio de Ciencia e Innovacion -Agencia Estatal de Investigacion [RTI2018-095872-B-C21/ERDF], Ministerio de Ciencia e Innovacion [SAF2016-80427-R, PID2019-108806RB-I00], Fundacio Marato TV3 [20172230, 20172231 and 20172110] Fundacion Step by Step, Agencia Valenciana de Innovacion (AVI) [INNVAL10/19/047] and MINECO/FEDER, UE; Fondo Europeo de Desarrollo Regional (FEDER) incluido en el Programa Operativo FEDER de la Comunidad Valenciana 2014-2020.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Transplantation of Human Fetal Spinal cord-derived NPCs Primed with a Polyglutamate-conjugated Rho/Rock Inhibitor as a Therapy for Acute Spinal Cord Injury

  • Giraldo, Esther|||0000-0001-5488-3011
  • Bonilla, Pablo
  • Mellado, Mara
  • García-Manau, Pablo
  • Rodó, Carlota
  • Alastrue, Ana
  • López, Eric
  • Carreras Moratonas, Elena
  • Pellisé, Ferran
  • Dordevic, Snezana
  • Vicent, María J.
  • Moreno Manzano, Victoria
[EN] Neural precursor cell (NPC) transplantation represents a promising therapy for treating spinal cord injuries (SCIs); however, despite successful results obtained in preclinical models, the clinical translation of this approach remains challenging due, in part, to the lack of consensus on an optimal cell source for human neuronal cells. Depending on the cell source, additional limitations to NPC-based therapies include high tumorigenic potential, alongside poor graft survival and engraftment into host spinal tissue. We previously demonstrated that NPCs derived from rat fetal spinal cords primed with a polyglutamate (PGA)-conjugated form of the Rho/Rock inhibitor fasudil (PGA-SS-FAS) displayed enhanced neuronal differentiation and graft survival when compared to non-primed NPCs. We now conducted a similar study of human-fetal-spinal-cord-derived NPCs (hfNPCs) from legal gestational interruptions at the late gestational stage, at 19-21.6 weeks. In vitro, expanded hfNPCs retained neural features, multipotency, and self-renewal, which supported the development of a cell banking strategy. Before transplantation, we established a simple procedure to prime hfNPCs by overnight incubation with PGA-SS-FAS (at 50 ¿M FAS equiv.), which improved neuronal differentiation and overcame neurite-like retraction after lysophosphatidic-acid-induced Rho/Rock activation. The transplantation of primed hfNPCs into immune-deficient mice (NU(NCr)-Foxn1nu) immediately after the eighth thoracic segment compression prompted enhanced migration of grafted cells from the dorsal to the ventral spinal cord, increased preservation of GABAergic inhibitory Lbx1-expressing and glutamatergic excitatory Tlx3-expressing somatosensory interneurons, and elevated the numbers of preserved, c-Fos-expressing, activated neurons surrounding the injury epicenter, all in a low percentage. Overall, the priming procedure using PGA-SS-FAS could represent an alternative methodology to improve the capabilities of the hfNPC lines for a translational approach for acute SCI treatment., This research was funded by Fundacio Marato TV3 2017/refs.20172230, 20172231, Agencia Valenciana de Innovacion (AVI) (INNVAL10/19/047 and Grants RTI2018-095872-B-C21 and PDI20211243590B-I00/ERDF funded by MCIN/AEI//10.13039/501100011033 and by ERDF A way of making Europe). This project was also funded by Project 964562 (RISEUP), H2020 FetOpen program.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Human-Induced Neural and Mesenchymal Stem Cell Therapy Combined with a Curcumin Nanoconjugate as a Spinal Cord Injury Treatment

  • Bonilla, Pablo
  • Hernandez, Joaquim
  • González-Pérez, Miguel A.
  • Alastrue-Agudo, Ana
  • Elkhenany, Hoda
  • Vicent, María J.
  • Edel, Michael
  • Moreno-Manzano, Victoria
  • Giraldo, Esther|||0000-0001-5488-3011
  • Navarro i García, Xavier
[EN] We currently lack effective treatments for the devastating loss of neural function associated with spinal cord injury (SCI). In this study, we evaluated a combination therapy comprising human neural stem cells derived from induced pluripotent stem cells (iPSC-NSC), human mesenchymal stem cells (MSC), and a pH-responsive polyacetal-curcumin nanoconjugate (PA-C) that allows the sustained release of curcumin. In vitro analysis demonstrated that PA-C treatment protected iPSC-NSC from oxidative damage in vitro, while MSC co-culture prevented lipopolysaccharide-induced activation of nuclear factor-kappa B (NF-kappa B) in iPSC-NSC. Then, we evaluated the combination of PA-C delivery into the intrathecal space in a rat model of contusive SCI with stem cell transplantation. While we failed to observe significant improvements in locomotor function (BBB scale) in treated animals, histological analysis revealed that PA-C-treated or PA-C and iPSC-NSC + MSC-treated animals displayed significantly smaller scars, while PA-C and iPSC-NSC + MSC treatment induced the preservation of beta-III Tubulin-positive axons. iPSC-NSC + MSC transplantation fostered the preservation of motoneurons and myelinated tracts, while PA-C treatment polarized microglia into an anti-inflammatory phenotype. Overall, the combination of stem cell transplantation and PA-C treatment confers higher neuroprotective effects compared to individual treatments., This research was funded by Fundacio Marato TV3 2017/refs.20172230, 20172231 and 20172110; FEDER/Ministerio de Ciencia e Innovacion-Agencia Estatal de Investigacion "RTI2018095872-B-C21/ERDF", Agencia Valenciana de Innovacion (AVI) INNVAL10/19/047 and TERCEL (RD12/0019/0011) funds from the Instituto de Salud Carlos III of Spain.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Optogenetic Modulation of Neural Progenitor Cells Improves Neuroregenerative Potential

  • Giraldo, Esther|||0000-0001-5488-3011
  • Palmero-Canton, David
  • Martínez-Rojas, Beatriz
  • Sanchez-Martin, Maria del Mar
  • Moreno-Manzano, Victoria
[EN] Neural progenitor cell (NPC) transplantation possesses enormous potential for the treatment of disorders and injuries of the central nervous system, including the replacement of lost cells or the repair of host neural circuity after spinal cord injury (SCI). Importantly, cell-based therapies in this context still require improvements such as increased cell survival and host circuit integration, and we propose the implementation of optogenetics as a solution. Blue-light stimulation of NPCs engineered to ectopically express the excitatory light-sensitive protein channelrhodopsin-2 (ChR2-NPCs) prompted an influx of cations and a subsequent increase in proliferation and differentiation into oligodendrocytes and neurons and the polarization of astrocytes from a pro-inflammatory phenotype to a pro-regenerative/anti-inflammatory phenotype. Moreover, neurons derived from blue-light-stimulated ChR2-NPCs exhibited both increased branching and axon length and improved axon growth in the presence of axonal inhibitory drugs such as lysophosphatidic acid or chondroitin sulfate proteoglycan. Our results highlight the enormous potential of optogenetically stimulated NPCs as a means to increase neuroregeneration and improve cell therapy outcomes for enhancing better engraftments and cell identity upon transplantation in conditions such as SCI., This research was funded by FEDER/Ministerio de Ciencia e Innovacion-Agencia Estatal de Investigacion "RTI2018-095872-B-C21/ERDF", Fundacio La Marato de TV3 2017/refs. 20172230, 20172231 and 20172110, Agencia Valenciana de Innovacion (AVI) INNVAL10/19/047, ACIF2019 and MINECO/FEDER, UE; Fondo Europeo de Desarrollo Regional (FEDER) included in the Programa Operativo FEDER de la Comunidad Valenciana 2014-2020.